Patents by Inventor Kyeong-Cheon Jung

Kyeong-Cheon Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD40L binding polypeptide
    Patent number: 10882911
    Abstract: Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 5, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: SeongHoe Park, Kyeong Cheon Jung
  • CD154 BINDING POLYPEPTIDE AND USE THEREOF
    Publication number: 20180194847
    Abstract: Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.
    Type: Application
    Filed: June 22, 2016
    Publication date: July 12, 2018
    Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: SeongHoe PARK, Kyeong Cheon JUNG
  • Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof
    Patent number: 9746474
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: August 29, 2017
    Assignee: DINONA INC.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
  • Antibody that binds domain 2 of ICAM-1 and methods of treatment
    Patent number: 9334326
    Abstract: Disclosed are a monoclonal antibody targeting domain 2 of ICAM-1 protein and a composition comprising the monoclonal antibody for treating or preventing T cell-mediated immune disease. The antibody of the present application induces antigen-specific T cell tolerance through the regulation of dendritic cell differentiation, and therefore, can be effectively used to treat or prevent autoimmune disease, organ or tissue transplant rejection, and graft-versus-host-disease.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: May 10, 2016
    Assignee: SNU R&DB FOUNDATION
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • ICAM-1 ANTIBODY AND USE THEREOF
    Publication number: 20150252111
    Abstract: Disclosed are a monoclonal antibody targeting domain 2 of ICAM-1 protein and a composition comprising the monoclonal antibody for treating or preventing T cell-mediated immune disease. The antibody of the present application induces antigen-specific T cell tolerance through the regulation of dendritic cell differentiation, and therefore, can be effectively used to treat or prevent autoimmune disease, organ or tissue transplant rejection, and graft-versus-host-disease.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 10, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
    Patent number: 9115198
    Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: August 25, 2015
    Assignee: Dinona Inc.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Youngmee Bae, Seong-Pyo Park, Yoon-Kyung Jeon
  • Antibody that binds domain 2 of ICAM-1 and methods of treatment
    Patent number: 8900586
    Abstract: The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: December 2, 2014
    Assignees: Dinona Inc., SNU R&DB Foundation
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • Acute Leukemia And Lymphoblastic Lymphoma-Specific CD43 Epitope and Use Thereof
    Publication number: 20140342374
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 20, 2014
    Applicant: Dinona Inc.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
  • Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof
    Patent number: 8753636
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 17, 2014
    Assignee: Dinona Inc.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
  • ANTIBODY INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE AND USE THEREOF
    Publication number: 20140148583
    Abstract: The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Application
    Filed: July 5, 2011
    Publication date: May 29, 2014
    Applicants: SNU R&DB FOUNDATION, DINONA INC.
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • Acute Leukemia And Lymphoblastic Lymphoma-Specific CD43 Epitope and Use Thereof
    Publication number: 20130287683
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 31, 2013
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
  • Acute leukemia and lymphoblastic lymphona-specific CD43 epitope
    Patent number: 8426555
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: April 23, 2013
    Assignee: Dinona Inc.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
  • Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof
    Publication number: 20120083589
    Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Application
    Filed: August 10, 2011
    Publication date: April 5, 2012
    Applicant: DINONA INC.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Youngmee Bae, Seong-Pyo Park, Yoon-Kyung Jeon
  • Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
    Patent number: 8026343
    Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: September 27, 2011
    Assignee: Dinona Inc.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Youngmee Bae, Seong-Pyo Park, Yoon-Kyung Jeon
  • ACUTE LEUKEMIA AND LYMPHOBLASTIC LYMPHONA-SPECIFIC CD43 EPITOPE AND USE THEREOF
    Publication number: 20100234562
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Application
    Filed: October 9, 2009
    Publication date: September 16, 2010
    Applicant: DINONA INC.
    Inventors: SEONG-HOE PARK, KYEONG-CHEON JUNG, EUN-YOUNG CHOI, SEONG-PYO PARK
  • Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
    Publication number: 20100168394
    Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Application
    Filed: March 24, 2009
    Publication date: July 1, 2010
    Applicant: SNU R& DB Foundation
    Inventors: SEONG-HOE PARK, KYEONG-CHEON JUNG, YOUNGMEE BAE, SEONG-PYO PARK, YOON-KYUNG JEON
  • Monoclonal antibody specific for CD43 epitope
    Patent number: 7622560
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: November 24, 2009
    Assignee: Dinona Inc.
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
  • Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof
    Publication number: 20070020179
    Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
    Type: Application
    Filed: December 20, 2005
    Publication date: January 25, 2007
    Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park